Carol Gallagher, Pharm. D., Chief Executive Officer
Dr. Gallagher joined Calistoga in September 2008 as Chief Executive Officer. She brings nearly 20 years experience in business and drug development at large and small biopharmaceutical companies. Prior to Calistoga, Dr. Gallagher was President and CEO of Metastatix, a private oncology company. In 2006, Dr. Gallagher served as Senior Vice President of Corporate Development for Anadys Pharmaceuticals, where she directed business development and commercial and strategic planning. From 2003 to 2006 she worked at CancerVax, where she served as Vice President of Product Planning. At CancerVax, Dr. Gallagher was part of the management team that executed the Canvaxin license with Serono and the subsequent reverse merger with Micromet, Inc.

Beginning in 2002, Dr. Gallagher led the Rituxan collaboration and oncology marketing at Biogen Idec. During her tenure at Biogen Idec, Dr. Gallagher led the Rituxan team when oncology sales first surpassed $1 billion and the rheumatoid arthritis and multiple sclerosis development programs were designed. Dr. Gallagher also led oncology and ophthalmology global marketing planning at Pfizer, joining Pfizer through the acquisition of Warner Lambert and Agouron Pharmaceuticals.

Dr. Gallagher began her career in sales and marketing at Eli Lilly and also held various sales and marketing roles at Amgen prior to joining Agouron Pharmaceuticals in 1997. She received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.

W. Michael Gallatin, Ph.D., President
Michael Gallatin has been President and a member of the Board of Directors since he co-founded Calistoga Pharmaceuticals in March 2006. Dr. Gallatin has more than 25 years of research and development experience in oncology, immunology, and vascular biology. Dr. Gallatin was one of the founding scientists at ICOS Corporation in 1990, most recently serving as Vice President and Scientific Director of ICOS Corporation before it was acquired by Eli Lilly and Company. Prior to joining ICOS, Dr. Gallatin was a faculty member of the Fred Hutchinson Cancer Research Center in Seattle, and an affiliate faculty member of the Department of Microbiology and Immunology at the University of Washington. He has been a member of the Scientific Advisory Board of the Keystone Symposia and Caprion and currently serves in that capacity for Stromedix Corporation and the University of Texas Department of Chemistry. He is a member of the BioSeek and Seredigm Boards of Directors. Dr. Gallatin also is a Venture Partner to the Biopharma team of Frazier Healthcare Ventures.

Dr. Gallatin received his Bachelor of Science in Zoology from Truman State University and was awarded a doctorate in Immunology from the University of Alberta, Department of Immunology. He undertook his postdoctoral training at Stanford University in the laboratory of Dr. Irving Weissman.

Neill Giese, Ph.D., Chief Scientific Officer
Neill Giese has been the Chief Scientific Officer at Calistoga Pharmaceuticals since he co-founded the company in 2006. Dr. Giese has 18 years of experience in drug discovery and development in oncology, inflammation and vascular biology with a focus on mechanism-based targeted therapies for the treatment of hematologic malignancies. Prior to Calistoga, Dr. Giese was Senior Vice President of Biological Sciences and Drug Development at SGX Inc.  Prior to SGX, Dr. Giese was one of the founding scientists at COR Therapeutics, Inc. in 1989, most recently serving as Senior Director of Cancer and Cardiovascular Biology continuing in that position after it was acquired by Millennium Pharmaceuticals.

Dr. Giese received his Bachelor of Science degree in Pharmacy and Masters of Science degree in Pharmacology and Toxicology from Oregon State University and his doctorate in Pharmacology from University of Arizona.  He undertook his postdoctoral training at the National Cancer Institute, National Institutes of Health in the laboratory of Dr. Stuart Aaronson.

Clifford J. Stocks, Chief Business Officer
Clifford Stocks joined Calistoga in March 2009 as Chief Business Officer. He brings more than two decades of experience in the biotech industry, including business and corporate development strategy and business practices. Mr. Stocks’ career includes 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007. Previously, he was a management consultant in the Health Services practice of Booz, Allen & Hamilton.

Mr. Stocks also serves on the Board of Sinova Pharmaceuticals Inc., a biotech startup in Shanghai, China. His career includes academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago.

Mr. Stocks received a Master of Business Administration degree from the University of Chicago Graduate School of Business, and a Bachelor of Science degree in biology from the University of Utah.

Roger Ulrich, Ph.D., Chief Development Officer
Roger Ulrich has been the Chief Development Officer at Calistoga Pharmaceuticals since co-founding the company in 2006. Dr. Ulrich has more than 24 years of drug discovery and development experience primarily in oncology, metabolic and infectious diseases. Prior to Calistoga, Dr, Ulrich was Senior Scientific Director with Merck Research Laboratories-Rosetta Inpharmatics where he led a team investigating molecular mechanisms and biomarkers for adverse drug reactions. Prior to Merck, Dr. Ulrich held various scientific and leadership positions including Director of Regulatory Toxicology and Safety Pharmacology with Abbott Laboratories, and as Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to that he worked at West Virginia and Michigan State Universities, and at Argonne National Laboratories. Dr. Ulrich has authored more than 115 publications and is an internationally recognized lecturer on toxicology, genomics and drug discovery. He continues to serve on various editorial boards, government and academic advisory boards and working committees.

Dr. Ulrich received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.

Albert S. Yu, M.D., Vice President, Clinical Affairs
and Chief Medical Officer
Albert Yu joined Calistoga Pharmaceuticals in 2007 as its Vice President of Clinical Affairs and Chief Medical Officer. Dr. Yu has more than 15 years experience in drug development at ICOS Corporation, where from 1992 to 2007 he held various positions in clinical affairs. He was responsible for managing the clinical department as well as overseeing clinical development of multiple product candidates, including in collaboration with Eli Lilly, the development of Cialis for the treatment of erectile dysfunction.

Dr. Yu received his Bachelor of Science degree in Biology from Massachusetts Institute of Technology and his medical degree from the University of Washington. Dr. Yu is trained in internal medicine, critical care medicine and pulmonary disease.